Therapeutic Advances in Multiple Sclerosis

Overview

Journal Front Neurol

Specialty Neurology

Date 2022 Jun 20

PMID 35720070

Authors

Jennifer H Yang

Torge Rempe

Natalie Whitmire

Anastasie Dunn-Pirio

Jennifer S Graves

Affiliations

Soon will be listed here.

Abstract

Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system that causes significant disability and healthcare burden. The treatment of MS has evolved over the past three decades with development of new, high efficacy disease modifying therapies targeting various mechanisms including immune modulation, immune cell suppression or depletion and enhanced immune cell sequestration. Emerging therapies include CNS-penetrant Bruton's tyrosine kinase inhibitors and autologous hematopoietic stem cell transplantation as well as therapies aimed at remyelination or neuroprotection. Therapy development for progressive MS has been more challenging with limited efficacy of current approved agents for inactive disease and older patients with MS. The aim of this review is to provide a broad overview of the current therapeutic landscape for MS.

Citing Articles

Exploring the Role of Positive Body Image, Depression Symptoms, Disability and Age in Acceptance of Illness in People with Multiple Sclerosis.

Matusik E, Lewicka B, Czepczor-Bernat K, Maciejowska K, Kowalcze P J Clin Med. 2025; 14(3).

PMID: 39941392 PMC: 11818923. DOI: 10.3390/jcm14030724.

Cloud and IoT based smart agent-driven simulation of human gait for detecting muscles disorder.

Saadati S, Sepahvand A, Razzazi M Heliyon. 2025; 11(2):e42119.

PMID: 39906796 PMC: 11791118. DOI: 10.1016/j.heliyon.2025.e42119.

Towards a biological view of multiple sclerosis from early subtle to clinical progression: an expert opinion.

Filippi M, Amato M, Avolio C, Gallo P, Gasperini C, Inglese M J Neurol. 2025; 272(2):179.

PMID: 39891770 PMC: 11787267. DOI: 10.1007/s00415-025-12917-4.

Effect of Different Treatments on Retinal Thickness Changes in Patients With Multiple Sclerosis: A Review.

Adibi A, Adibi I, Javidan M CNS Neurosci Ther. 2025; 31(1):e70225.

PMID: 39853938 PMC: 11759887. DOI: 10.1111/cns.70225.

Real-world satisfaction and experience with injection and autoinjector device for ofatumumab indicated for multiple sclerosis.

Ross A, Nicholas J, Tai M, Yeung S, Shaikh N, Chen H BMC Neurol. 2025; 25(1):28.

PMID: 39833702 PMC: 11744959. DOI: 10.1186/s12883-024-04007-1.

References

Kunkl M, Frascolla S, Amormino C, Volpe E, Tuosto L . T Helper Cells: The Modulators of Inflammation in Multiple Sclerosis. Cells. 2020; 9(2). PMC: 7072830. DOI: 10.3390/cells9020482. View

Jones J, Phuah C, Cox A, Thompson S, Ban M, Shawcross J . IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest. 2009; 119(7):2052-61. PMC: 2701868. DOI: 10.1172/JCI37878. View

Cencioni M, Mattoscio M, Magliozzi R, Bar-Or A, Muraro P . B cells in multiple sclerosis - from targeted depletion to immune reconstitution therapies. Nat Rev Neurol. 2021; 17(7):399-414. DOI: 10.1038/s41582-021-00498-5. View

Subei A, Cohen J . Sphingosine 1-phosphate receptor modulators in multiple sclerosis. CNS Drugs. 2015; 29(7):565-75. PMC: 4554772. DOI: 10.1007/s40263-015-0261-z. View

Monti D, Zabrecky G, Leist T, Wintering N, Bazzan A, Zhan T . N-acetyl Cysteine Administration Is Associated With Increased Cerebral Glucose Metabolism in Patients With Multiple Sclerosis: An Exploratory Study. Front Neurol. 2020; 11:88. PMC: 7033492. DOI: 10.3389/fneur.2020.00088. View

Calabresi P, Kieseier B, Arnold D, Balcer L, Boyko A, Pelletier J . Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014; 13(7):657-65. DOI: 10.1016/S1474-4422(14)70068-7. View

Pender M, Csurhes P, Smith C, Beagley L, Hooper K, Raj M . Epstein-Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis. Mult Scler. 2014; 20(11):1541-4. PMC: 4230458. DOI: 10.1177/1352458514521888. View

McKay K, Kwan V, Duggan T, Tremlett H . Risk factors associated with the onset of relapsing-remitting and primary progressive multiple sclerosis: a systematic review. Biomed Res Int. 2015; 2015:817238. PMC: 4329850. DOI: 10.1155/2015/817238. View

Hecker M, Fitzner B, Jager K, Buhring J, Schwartz M, Hartmann A . Leukocyte Telomere Length in Patients with Multiple Sclerosis and Its Association with Clinical Phenotypes. Mol Neurobiol. 2021; 58(6):2886-2896. PMC: 8128833. DOI: 10.1007/s12035-021-02315-y. View

10.

Zarbin M, Jampol L, Jager R, Reder A, Francis G, Collins W . Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis. Ophthalmology. 2013; 120(7):1432-9. DOI: 10.1016/j.ophtha.2012.12.040. View

11.

Dhib-Jalbut S, Marks S . Interferon-beta mechanisms of action in multiple sclerosis. Neurology. 2009; 74 Suppl 1:S17-24. DOI: 10.1212/WNL.0b013e3181c97d99. View

12.

Lassmann H . Mechanisms of white matter damage in multiple sclerosis. Glia. 2014; 62(11):1816-30. DOI: 10.1002/glia.22597. View

13.

Cohen J, Coles A, Arnold D, Confavreux C, Fox E, Hartung H . Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012; 380(9856):1819-28. DOI: 10.1016/S0140-6736(12)61769-3. View

14.

Laplaud D, Casey R, Barbin L, Debouverie M, De Seze J, Brassat D . Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis. Neurology. 2019; 93(7):e635-e646. PMC: 6715507. DOI: 10.1212/WNL.0000000000007938. View

15.

Popescu B, Lucchinetti C . Meningeal and cortical grey matter pathology in multiple sclerosis. BMC Neurol. 2012; 12:11. PMC: 3315403. DOI: 10.1186/1471-2377-12-11. View

16.

Krysko K, Graves J, Rensel M, Weinstock-Guttman B, Rutatangwa A, Aaen G . Real-World Effectiveness of Initial Disease-Modifying Therapies in Pediatric Multiple Sclerosis. Ann Neurol. 2020; 88(1):42-55. DOI: 10.1002/ana.25737. View

17.

Harding K, Williams O, Willis M, Hrastelj J, Rimmer A, Joseph F . Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis. JAMA Neurol. 2019; 76(5):536-541. PMC: 6515582. DOI: 10.1001/jamaneurol.2018.4905. View

18.

Kappos L, Bar-Or A, Cree B, Fox R, Giovannoni G, Gold R . Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018; 391(10127):1263-1273. DOI: 10.1016/S0140-6736(18)30475-6. View

19.

Freedman M, Devonshire V, Duquette P, Giacomini P, Giuliani F, Levin M . Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations. Can J Neurol Sci. 2020; 47(4):437-455. DOI: 10.1017/cjn.2020.66. View

20.

. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993; 43(4):655-61. DOI: 10.1212/wnl.43.4.655. View